The benefit of hypothermic targeted temperature management decreases when post-arrest care improves
===================================================================================================

* Wei-Ting Chen
* Yu-Tzu Tien
* Chien-Hua Huang
* Chih-Hung Wang
* Wei-Tien Chang
* Hooi-Nee Ong
* Wen-Jone Chen
* Min-Shan Tsai

## Abstract

**Background** Several clinical trials and cohort studies in the past two decades have demonstrated inconsistent results regarding survival and neurologic recovery benefits for patients undergoing targeted temperature management (TTM) at 33℃ as compared to those undergoing TTM at 36℃ or normothermia. Whether the improved quality of post-arrest care over time contributes to diminishing benefit of TTM at 33℃ remains un-investigated.

**Methods** There were 1,809 adult non-traumatic cardiac arrest survivors during 2011-2020. After excluding patients with pre-arrest poor conscious level defined as Glasgow-Pittsburgh Cerebral Performance Category (CPC) >2 (n=258), patients who regained clear consciousness after return of spontaneous circulation (ROSC) (n=300), patients with active bleeding or intracranial hemorrhage (n=48) and patients who underwent TTM of 36℃ due to unstable hemodynamic (n=11), a total of 1,192 eligible candidates for TTM of 33℃ were finally enrolled and classified into Period 1 (during 2011-2015, n = 449) and Period 2 (during 2016-2020, n = 693).

**Results** Patients in Period 2 received more diagnostics procedures and specific therapies than those in Period 1. The proportion of patients with good neurological recovery at hospital discharge in Period 2 is significantly higher than that in Period 1 (21.4% vs.14.0%, adjusted odds ratio [aOR] 1.60, 95% confidence interval [CI] 1.14-2.26). TTM was beneficial for the outcomes in both Period 1 and 2, with patients in Period 1 having higher chances of survival and good neurological outcome than those in Period 2 (survival: aOR 5.66, 95% CI 3.49-9.18 vs. aOR 2.91, 95% CI 1.98-4.28; good neurological recovery: aOR 3.92, 95% CI 2.12-7.25 vs. aOR 2.19, 95% CI 1.43-3.34). Among patients with low-risk and medium-risk severity of illness, TTM benefited survival and neurological outcomes, regardless of time period. But the chance of beneficial outcomes decreased consistently from Period 1 to Period 2.

**Conclusion** Among cardiac arrest survivors, improvement in the quality of post-cardiac arrest care over time is associated with better neurological recovery. TTM remains beneficial for survival and neurological outcomes following cardiac arrest, regardless of the time period. However, the benefit of TTM may diminish when post-cardiac arrest care improves.

Keywords
*   Cardiac arrest
*   neurological recovery
*   targeted temperature management
*   33°C
*   protocolization

## Background

In recent decade, the dispute whether preventing fever following return of spontaneous circulation (ROSC) rather than reducing body temperature to 33℃ was enough to alleviate post-arrest brain injury has been raised, since the TTM and TTM2 trials demonstrated no difference in survival and neurological outcomes between patients underwent TTM of 33℃ vs. 36℃,1 or vs. <37.8℃,2. However, several retrospective cohort studies have shown less protocol compliance3 and more fever during the early post-arrest period,3,4 and thus worse survival and neurological recovery in patients underwent targeted temperature management (TTM) of 36℃.4–6 Moreover, the HYPERION trial demonstrated better neurological recovery in TTM of 33℃ than normothermia among patients with non-shockable rhythm.7 The severity of post-cardiac arrest syndrome was proposed to account for the discrepancies between these studies. Better outcomes were observed when temperature was targeted at 33℃ in the patients with moderate-severity.8,9

In addition to illness severity, the benefit of protocolized post-arrest care in the trials may also attribute to the insignificant difference between hypothermia and normothermia. The importance of post-cardiac arrest care began to be emphasized since 2010, and a multidisciplinary, systemic approach of care was proposed, including optimization of ventilation and hemodynamics, neurologic management, glycemic control, TTM and immediate coronary revascularization.10,11 Our previous study demonstrated that these practices help improve the quality of care in patients without TTM.12 However, whether benefit of therapeutic hypothermia over no temperature management decreases along with the improved post-arrest care remains uninvestigated. Before the launch of the 2015 American Heart Association (AHA) guidelines, the National Taiwan University Hospital (NTUH) only used the TTM protocol with a target temperature of 33℃. Since 2016 January, the NTUH protocol has been revised to subject stable patients to TTM at 33℃ while only a few patients with unstable hemodynamics or arrhythmia are treated at 36℃. The aim of this study was to examine the benefit of hypothermic TTM at 33℃ on survival and favorable neurologic recovery during the time period from 2010 to 2020, in the context of the improvements of post-arrest care.

## Methods

### Demographics/Epidemiology

This retrospective cohort study was conducted at National Taiwan University Hospital, a 2500-bed tertiary medical center located in Taipei City with 110,000 annual emergency department visits13. The Institutional Review Board of NTUH approved the study(202111079RINA) and waived participant consent.

#### Participants Selection

The study enrolled 1,809 adult, non-traumatic cardiac arrest victims with successful resuscitation between January 2011 and December 2020 in the ED of NTUH. Patients were excluded if they had a pre-arrest poor consciousness level, defined as Glasgow-Pittsburgh Cerebral Performance Category (CPC)>2 (n=258), had regained clear consciousness within 3 hours after ROSC (n=300), had massive bleeding or intracranial hemorrhage at ROSC (n=48), and who underwent TTM with a target temperature of 36℃ due to unstable hemodynamics (n=11). A total of 1,192 eligible candidates for TTM with target temperature at 33℃ were finally enrolled in the current study. When further classified by the AHA guidelines revised in Dec 2015, 449 patients with an index cardiac arrest between 2011-2015 were further classified as “Period 1”, and 693 patients with an index cardiac arrest between 2016-2020 were classified as “Period 2” (Figure 1).

![Figure 1.](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/05/24/2023.05.22.23290369/F1.medium.gif)

[Figure 1.](http://medrxiv.org/content/early/2023/05/24/2023.05.22.23290369/F1)

Figure 1. The flowchart of enrolled patients
CPC, Glasgow-Pittsburgh Cerebral Performance Category; ICH, intracranial hemorrhage; ROSC, return of spontaneous circulation; TTM, targeted temperature management.

#### TTM Protocol of NTUH

NTUH is the first hospital in Taiwan to introduce TTM for cardiac arrest survivors, and has established a protocol for TTM since 2003. After the application of cooling devices was approved by the Taiwan Ministry of Health and Welfare in 2005, the first patient underwent TTM in 2006. The protocols for post-cardiac arrest care, including TTM, were updated sequentially in alignment with the 2010, 2015 and 2020 AHA guidelines.10,14,15 Before the launch of 2020 AHA guideline, the cardiac arrest survivors underwent TTM at 33°C except for those with unstable hemodynamic even with more than 2 inotropes support in the early post-arrest period and those with massive bleeding or intracranial hemorrhage after ROSC. Cold saline and cooling devices with auto-feedback were used to reduce patients’ body temperatures to the target temperature of 33°C within 4–6 hours after ROSC, maintain target temperature for 24 hours, and rewarm patients at the rate of 0.25°C per hour until 36°C was achieved. Temperature management was continued for another 24 hours after rewarming to avoid fever 13.

#### Data Collection and Variables Definition

The primary data set was obtained from the hospital medical record data repository and included demographic information, past medical history, prehospital arrest events, cardiac arrest details, post-arrest management, laboratory examinations, and disposition. This study followed Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines.16

Patients with cardiac arrest were considered as either those with out-of-hospital cardiac arrest (OHCA), with in-hospital cardiac arrest (IHCA) after triage, or those who achieved ROSC before being transferred from another hospital. Cardiogenic arrest was recorded when ischemic heart disease, structural heart disease, heart failure, or arrhythmia without an electrolyte imbalance was considered the cause of arrest. The causes of cardiac arrest were determined by the responsible primary care physicians, who were blinded to the current study. Repeated CPR was defined as another episode of arrest within one hour after initial ROSC.

Overall cardiac arrest severity was assigned using the simplified Cardiac Arrest Hospital Prognosis (sCAHP) score as our previous publication, which excluded the no-flow interval data with similar predictive accuracy as the original score in an East Asian population.17 The illness severity (≤150 as low-risk, 151-199 as medium-risk, and ≥200 as high-risk) was determined by using the method with a scheme that used significant F-values for cut-off points.18 The performance of illness severity categorized by the sCAHP score (our data) and the CAHP score (Sudden Death Expertise Center registry, Paris, France)19 is shown in Supplementary Table 1.

During the early post-arrest period, electrocardiogram (ECG), echocardiography and cerebral computed tomography after ROSC were recorded. Emergent coronary angiography (CAG) was recorded when indicated patients underwent CAG within 24 hours after ROSC. Extracorporeal membrane oxygenation (ECMO) was recorded when applied as indicated during index resuscitation. Fever (≥38.3°C), infection workup, electroencephalogram (EEG) and anti-epileptic drugs (AED) use during first 3 days after ROSC were documented.

#### Outcome Measures

The primary outcome was favorable neurological recovery at hospital discharge, defined as a CPC of 1 (good recovery) or 2 (moderate disability). The secondary outcomes include survival at hospital discharge, as well as at 3-month and 1-year follow-ups. CPC at hospital discharge was evaluated by primary care physicians who were blinded to the current study.

### Patient and public involvement

The patients and public were not involved in the creation of the study design, recruitment or statistical analysis. Patients were not consulted to develop patient relevant outcomes or interpret the results. Patients were not invited to contribute to the writing or editing of this manuscript.

#### Statistical Analysis

Descriptive statistics were presented as frequencies for categorical variables and the median with interquartile ranges for continuous variables. For 2 group comparison, Fisher’s exact or Pearson’s chi-squared test for categorical variables, and the Mann-Whitney U test for continuous variables were used. Multiple imputation (Markov Chain Monte Carlo) was used for missing data of laboratory examinations. Multivariable logistic regression models were used to examine the association between outcomes and time periods, and the benefit of hypothermic TTM over non-TTM on survival and good neurological recovery. All statistical analyses were performed using SPSS Statistics for Windows, version 16.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was assessed using two-sided 95% confidence intervals (CI) and a p<0.05.

## Results

### Period 1 vs. Period 2

A comparison of the patient characteristics, cardiac arrest events, and laboratory examinations between the two time periods is presented in Table 1. As compared with Period 1, the proportion of coronary artery disease, arrhythmia, OHCA, witnessed collapse, initial shockable rhythm and bystander CPR were higher during Period 2. But the adrenaline dosage, systolic blood pressure at ROSC, PH and HCO3 of blood gas were lower in patients during Period 2 than Period 1. Patients in Period 2 had higher sCAHP severity and APACHE II scores than those in Period 1. More patients in Period 2 received echocardiography, brain CT, emergent CAG, TTM and inotrope support following ROSC as well as EEG and AEDs within 3 days after cardiac arrest. Patients in Period 1 had longer duration from cooling to target temperature and greater highest body temperature when compared with those in Period 2. Increased active withdrawal was also noted in Period 2 (Table 2).

View this table:
[Table 1.](http://medrxiv.org/content/early/2023/05/24/2023.05.22.23290369/T1)

Table 1. Comparison of patient characteristics between time periods

View this table:
[Table 2.](http://medrxiv.org/content/early/2023/05/24/2023.05.22.23290369/T2)

Table 2. Comparison of post-arrest care between time periods

A representation of the proportion of patients that did not survive to hospital discharge, with poor CPC, and with good CPC between the two time periods can be seen in Figure 2. Mortality rates are comparable with 71.1% in Period 1 and 72.2% in Period 2. The chance of patients with good neurological recovery at ICU discharge (adjusted OR [aOR] 1.79, 95% CI=1.27-2.51) and hospital discharge (aOR 1.60, 95% CI=1.14-2.26) in Period 2 was significantly higher than in Period 1. There were no difference of 3-month and 1-year survival between Period 1 and Period 2 (Table 3).

![Figure 2.](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/05/24/2023.05.22.23290369/F2.medium.gif)

[Figure 2.](http://medrxiv.org/content/early/2023/05/24/2023.05.22.23290369/F2)

Figure 2. Comparison of Outcomes between Time Periods
CPC, Glasgow-Pittsburgh Cerebral Performance Category

View this table:
[Table 3.](http://medrxiv.org/content/early/2023/05/24/2023.05.22.23290369/T3)

Table 3. Comparison of outcomes between time periods

### Non-TTM vs. hypothermic TTM

There were 374 patients receiving hypothermic TTM following ROSC classified as the TTM group and the rest 818 patients classified as the non-TTM group. A comparison of underlying characteristics, cardiac arrest events, and laboratory results between patients with and without TTM treatment are presented in Supplementary Table 2. The patients in the TTM group were younger than those in the non-TTM group and suffered from less pre-arrest co-morbidity, such as bed-ridden and malignancy. Compared with the non-TTM group, the TTM group had a higher proportion of patients with OHCA, initial shockable rhythm, prehospital CPR, prehospital ROSC and presumed cardiogenic arrest, but less percentage of repeated CPR and high-risk severity. Besides, the TTM group required a lower adrenaline dosage, and had lower APACHE II scores but higher heart rates, systolic blood pressures, hemoglobin and platelet concentrations than the non-TTM group. Supplementary Table 3 demonstrates better post-arrest care in the TTM group than the non-TTM group including more cardiovascular and cerebral evaluations, better adherence to ventilation and hemodynamic recommendations, more infection workups, and early seizure detection and treatment. A comparison between the TTM and non-TTM groups in each time period is shown in Supplementary Tables 4 and 5.

Although significant interaction between time period and TTM was noted, both Period 2 and TTM remained associated with improved neurological recovery (Supplementary Table 6). Compared with the non-TTM group, patients who underwent TTM had better survival (aOR 3.67, 95% CI=2.73-4.93) and neurological outcome (aOR 2.71, 95% CI=1.92-3.82). TTM remained beneficial in both Period 1 and Period 2, and the benefit of TTM over non-TTM in survival and neurological recovery was higher in Period 1 as compared to Period 2 (survival: aOR 5.66, 95% CI=3.49-9.18 vs. aOR 2.91, 95% CI=1.98-4.28; good neurological recovery: aOR 3.92, 95% CI=2.12-7.25 vs. aOR 2.19, 95% CI=1.43-3.34). The enrolled patients were further stratified by sCAHP severity with 248 patients of low-risk severity, 547 patients of medium-risk severity and 397 patients of high-risk severity, respectively. Among patients with low- and medium-risk severity, TTM benefited survival and neurological outcomes, regardless of time period. But the chance for good outcomes consistently decreased from Period 1 to Period 2 in both low- and medium-risk subgroups. There was no significant benefit of TTM in patients with high-risk severity (Figure 3).

![Figure 3.](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/05/24/2023.05.22.23290369/F3.medium.gif)

[Figure 3.](http://medrxiv.org/content/early/2023/05/24/2023.05.22.23290369/F3)

Figure 3. The benefit of TTM over non-TTM in survival and neurological outcomes
Non-TTM as reference group, CPC=1-2 was considered as favorable neurological recovery

Ϯ adjusted by age, initial shockable rhythm, witnessed collapse, and CPR duration groups

aOR, adjusted odds ratio; CI, confidence interval; CPC, cerebral performance category; TTM, targeted temperature management

## Discussion

In this study, Period 2 had better post-arrest care than Period 1, and the neurological recovery improved significantly in Period 2. TTM were beneficial for survival and neurological outcomes among cardiac arrest patients in both time periods, especially in those with low- and medium-risk severity; however, its benefit diminished over time.

To alleviate post-cardiac arrest syndrome, bundle care focused on identifying the cause of arrest and preventing recurrence, providing ventilation to minimize lung injury, optimizing cardiovascular function, early detecting and treating post-arrest seizure, reducing risk of multiorgan injury, and controlling body temperature has been suggested by AHA guidelines since 2010.10 In the current study, patients in Period 2 had increased diagnostics procedures performed and specific therapies given for timely and appropriate management than those in Period 1. Although both short-term and long-term survival are comparable between Period 1 and Period 2, the benefit of improved post-cardiac arrest care might be reflected in more favorable neurological recovery in Period 2. The increased active withdrawal for patients with potentially poor neurological outcome and “do-not-attempt resuscitation” after ROSC in Period 2 may account for the insignificant difference in survival at hospital discharge between these 2 periods. Besides, the finding that approximately half of the patients discharged from the hospital died within 3 months emphasizes the importance of rehabilitation and health care after hospital discharge. Further studies are warrant to investigate the causes of death after hospital discharge.

In our current study, TTM at 33℃ remains beneficial in both time periods. The benefits of hypothermic TTM over non-TTM decreased in Period 2 in all enrolled patients as well as subgroups stratified by illness severity. The improved post-arrest care may account for this finding since the interventions were in place for all successfully resuscitated victims, regardless of TTM treatments. This finding also raises another important question—*Does the benefit of TTM on outcomes truly result from TTM or the protocolized care established along with TTM?* Laboratory animal studies displayed that therapeutic hypothermia at 32-33 °C ameliorated myocardial injury and brain damage after ischaemia/reperfusion injury, and thus, improved survival and neurological recovery.20,21 However, clinical trials showed inconsistent results concerning the benefit of TTM at 33 °C as compared with normothermia or no temperature control.1,2,7,22,23

Bernard et al., HACA and HYPERION trials demonstrated improved survival and neurological outcomes in patients underwent therapeutic hypothermia at 33 °C.7,22,23 However, the TTM trial demonstrated no difference in survival and neurological recovery between patients receiving TTM at 33 °C and 36 °C, emphasizing the importance of temperature control rather than the low target temperature.1 In 2021, the TTM2 trial once again demonstrated no outcome benefit in patients receiving TTM at 33 °C compared with those <37.8 °C, implying that aggressively preventing fever may be the main determinant factor.2 The evolution of post-cardiac arrest care within the two decades may account for the inconsistent results of these trials. Similar situation can be observed in the care of sepsis. The ARISE trial failed to show the benefit of early goal-directed therapy(EGDT) in reducing mortality, and the improvement of medical care quality along with the protocol establishment was proposed as a reason for comparable outcomes in the EGDT and control groups.24 The protocolized approaches usually facilitate medical teams to provide more consistent care and overcome barriers.25,26 Our results supported the hypothesis that the improved quality of post-arrest care would diminish the benefit of TTM on outcomes. Several retrospective cohort studies also demonstrated worse outcomes in patients with less adherence to protocols of temperature control. 3–5 Similar diminished difference between intervention and standard groups can also be observed in the Box trial: no outcome difference between different blood-pressure targets and different oxygen targets in cardiac arrest survivors. 27,28

### Limitation

This study had several limitations. First, due to the its retrospective nature, selection bias was unavoidable, and unidentified confounding factors or improvement of post-arrest care might be present. Second, the post-cardiac arrest care in the TTM group were better than that in the non-TTM group. The frequency of CT, emergent CAG and EEG of the TTM group were comparable with those in published studies.2,5,9 However, there is a lack of studies reporting the quality of post-arrest care in patients without TTM and we cannot compare our results with others. Nevertheless, our results indicated that much room for us to improve the care quality in patients without TTM. And the care discrepancy between the TTM and non-TTM groups might be the primary source of the TTM benefit as we hypothesized. Third, the reasons for patients not undergoing TTM were not recorded. The socioeconomic status of these patients, which might affect willingness to undergo TTM, was also not considered. However, standard ICU and post-arrest care are covered by National Health Insurance in Taiwan, and TTM was incorporated into the coverage in October 2015. Additionally, the neurological function was not recorded during the follow-up after hospital discharge. Finally, our study investigated a homogenous Asian population, and great caution should be exercised when attempting to extrapolate our results to other races.

## Conclusion

Among cardiac arrest survivors, the improved quality of post-cardiac arrest care over time is associated with better neurological recovery. Regardless of the time periods, hypothermic TTM remained beneficial to survival and neurological outcomes following cardiac arrest. However, benefit of TTM over non-TTM might be diminished along with improvement in post-cardiac arrest care.

## Declarations

### Ethics approval and consent to participate

This retrospective cohort study was approved by the Institutional Review Board of NTUH (202111079RINA) and waived participant consent.

### Consent for publication

not applicable

### Availability of data and material

The data sets used and analysed during the current study are available from the corresponding author on reasonable request

### Competing interests

The authors declare that they have no competing interests.

### Funding

not applicable

### Authors’ contributions

All authors contributed to the study conception and design. Material preparation and data collection were performed by CWT and OHN. The analysis was performed by TMS, TYT and WCH. The first draft of the manuscript was written by CWT. TMS, HCH and CWJ revised it critically for important intellectual content.

## Data Availability

All data are available in the manuscript.

## Acknowledgements

The authors would like to express their thanks to the staff of National Taiwan University Hospital-Statistical Consulting Unit (NTUH-SCU) for statistical consultation.

*   Received May 22, 2023.
*   Revision received May 22, 2023.
*   Accepted May 24, 2023.


*   © 2023, Posted by Cold Spring Harbor Laboratory

The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.

## References

1.  1.Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J, Hovdenes J, Kjaergaard J, Kuiper M, et al. Targeted temperature management at 33 degrees C versus 36 degrees C after cardiac arrest. N Engl J Med. 2013;369:2197–2206. doi: 10.1056/NEJMoa1310519
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa1310519&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24237006&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F05%2F24%2F2023.05.22.23290369.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000327801100006&link_type=ISI) 

2.  2.Dankiewicz J, Cronberg T, Lilja G, Jakobsen JC, Levin H, Ullen S, Rylander C, Wise MP, Oddo M, Cariou A, et al. Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest. N Engl J Med. 2021;384:2283–2294. doi: 10.1056/NEJMoa2100591
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2100591&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F05%2F24%2F2023.05.22.23290369.atom) 

3.  3.Bray JE, Stub D, Bloom JE, Segan L, Mitra B, Smith K, Finn J, Bernard S. Changing target temperature from 33 degrees C to 36 degrees C in the ICU management of out-of-hospital cardiac arrest: A before and after study. Resuscitation. 2017;113:39–43. doi: 10.1016/j.resuscitation.2017.01.016
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.resuscitation.2017.01.016&link_type=DOI) 

4.  4.Salter R, Bailey M, Bellomo R, Eastwood G, Goodwin A, Nielsen N, Pilcher D, Nichol A, Saxena M, Shehabi Y, et al. Changes in Temperature Management of Cardiac Arrest Patients Following Publication of the Target Temperature Management Trial. Crit Care Med. 2018;46:1722–1730. doi: 10.1097/CCM.0000000000003339
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/CCM.0000000000003339&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F05%2F24%2F2023.05.22.23290369.atom) 

5.  5.Johnson NJ, Danielson KR, Counts CR, Ruark K, Scruggs S, Hough CL, Maynard C, Sayre MR, Carlbom DJ. Targeted Temperature Management at 33 Versus 36 Degrees: A Retrospective Cohort Study. Crit Care Med. 2020;48:362–369. doi: 10.1097/CCM.0000000000004159
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/CCM.0000000000004159&link_type=DOI) 

6.  6.Minini A, Annoni F, Peluso L, Bogossian EG, Creteur J, Taccone FS. Which Target Temperature for Post-Anoxic Brain Injury? A Systematic Review from “Real Life” Studies. Brain Sci. 2021;11. doi: 10.3390/brainsci11020186
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3390/brainsci11020186&link_type=DOI) 

7.  7.Lascarrou JB, Merdji H, Le Gouge A, Colin G, Grillet G, Girardie P, Coupez E, Dequin PF, Cariou A, Boulain T, et al. Targeted Temperature Management for Cardiac Arrest with Nonshockable Rhythm. N Engl J Med. 2019;381:2327–2337. doi: 10.1056/NEJMoa1906661
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa1906661&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F05%2F24%2F2023.05.22.23290369.atom) 

8.  8.Callaway CW, Coppler PJ, Faro J, Puyana JS, Solanki P, Dezfulian C, Doshi AA, Elmer J, Frisch A, Guyette FX, et al. Association of Initial Illness Severity and Outcomes After Cardiac Arrest With Targeted Temperature Management at 36 degrees C or 33 degrees C. JAMA Netw Open. 2020;3:e208215. doi: 10.1001/jamanetworkopen.2020.8215
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jamanetworkopen.2020.8215&link_type=DOI) 

9.  9.Nishikimi M, Ogura T, Nishida K, Hayashida K, Emoto R, Matsui S, Matsuda N, Iwami T. Outcome Related to Level of Targeted Temperature Management in Postcardiac Arrest Syndrome of Low, Moderate, and High Severities: A Nationwide Multicenter Prospective Registry. Crit Care Med. 2021;49:e741–e750. doi: 10.1097/CCM.0000000000005025
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/CCM.0000000000005025&link_type=DOI) 

10. 10.Peberdy MA, Callaway CW, Neumar RW, Geocadin RG, Zimmerman JL, Donnino M, Gabrielli A, Silvers SM, Zaritsky AL, Merchant R, et al. Part 9: post-cardiac arrest care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122:S768–786. doi: 10.1161/circulationaha.110.971002
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MTQ6ImNpcmN1bGF0aW9uYWhhIjtzOjU6InJlc2lkIjtzOjE5OiIxMjIvMThfc3VwcGxfMy9TNzY4IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjMvMDUvMjQvMjAyMy4wNS4yMi4yMzI5MDM2OS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

11. 11.Chen WT, Tsai MS, Huang CH, Chang WT, Chen WJ. Protocolized Post-Cardiac Arrest Care with Targeted Temperature Management. Acta Cardiol Sin. 2022;38:391–399. doi: 10.6515/ACS.202205_38(3).20211220A
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.6515/ACS.202205_38(3).20211220A&link_type=DOI) 

12. 12.Ling DA HC, Chen WJ, Chuang PY, Chang WT, Sung CW, Chen WT, Ong HN, Tsai MS. Impact of protocolized postarrest care with targeted temperature management on the outcomes of cardiac arrest survivors without temperature management. Ann Med. 2022;54:63–70.
    
    

13. 13.Lin JJ, Huang CH, Chen WJ, Chuang PY, Chang WT, Chen WT, Tsai MS. Targeted temperature management and emergent coronary angiography are associated with improved outcomes in patients with prehospital return of spontaneous circulation. J Formos Med Assoc. 2020;119:1259–1266. doi: 10.1016/j.jfma.2020.03.017
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jfma.2020.03.017&link_type=DOI) 

14. 14.Neumar RW, Shuster M, Callaway CW, Gent LM, Atkins DL, Bhanji F, Brooks SC, de Caen AR, Donnino MW, Ferrer JM, et al. Part 1: Executive Summary: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015;132:S315–367. doi: 10.1161/CIR.0000000000000252
    
    [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MTQ6ImNpcmN1bGF0aW9uYWhhIjtzOjU6InJlc2lkIjtzOjE5OiIxMzIvMThfc3VwcGxfMi9TMzE1IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjMvMDUvMjQvMjAyMy4wNS4yMi4yMzI5MDM2OS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

15. 15.Panchal AR, Bartos JA, Cabañas JG, Donnino MW, Drennan IR, Hirsch KG, Kudenchuk PJ, Kurz MC, Lavonas EJ, Morley PT, et al. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020;142:S366–s468. doi: 10.1161/cir.0000000000000916
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1161/CIR.0000000000000916&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F05%2F24%2F2023.05.22.23290369.atom) 

16. 16.Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M, Initiative S. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. International journal of surgery. 2014;12:1500–1524. doi: 10.1016/j.ijsu.2014.07.014
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ijsu.2014.07.014&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25046751&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F05%2F24%2F2023.05.22.23290369.atom) 

17. 17.Wang CH, Huang CH, Chang WT, Tsai MS, Yu PH, Wu YW, Chen WJ. Prognostic performance of simplified out-of-hospital cardiac arrest (OHCA) and cardiac arrest hospital prognosis (CAHP) scores in an East Asian population: A prospective cohort study. Resuscitation. 2019;137:133–139. doi: 10.1016/j.resuscitation.2019.02.015
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.resuscitation.2019.02.015&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F05%2F24%2F2023.05.22.23290369.atom) 

18. 18.Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61:277–284. doi: 10.1016/0304-3959(94)00178-H
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/0304-3959(94)00178-H&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=7659438&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F05%2F24%2F2023.05.22.23290369.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1995QZ79300014&link_type=ISI) 

19. 19.Maupain C, Bougouin W, Lamhaut L, Deye N, Diehl JL, Geri G, Perier MC, Beganton F, Marijon E, Jouven X, et al. The CAHP (Cardiac Arrest Hospital Prognosis) score: a tool for risk stratification after out-of-hospital cardiac arrest. Eur Heart J. 2016;37:3222–3228. doi: 10.1093/eurheartj/ehv556
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/eurheartj/ehv556&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26497161&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F05%2F24%2F2023.05.22.23290369.atom) 

20. 20.Tsai MS, Huang CH, Tsai CY, Chen HW, Cheng HJ, Hsu CY, Chang WT, Chen WJ. Combination of intravenous ascorbic acid administration and hypothermia after resuscitation improves myocardial function and survival in a ventricular fibrillation cardiac arrest model in the rat. Acad Emerg Med. 2014;21:257–265. doi: 10.1111/acem.12335
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/acem.12335&link_type=DOI) 

21. 21.Huang CH, Tsai MS, Chiang CY, Su YJ, Wang TD, Chang WT, Chen HW, Chen WJ. Activation of mitochondrial STAT-3 and reduced mitochondria damage during hypothermia treatment for post-cardiac arrest myocardial dysfunction. Basic Res Cardiol. 2015;110:59. doi: 10.1007/s00395-015-0516-3
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00395-015-0516-3&link_type=DOI) 

22. 22.Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, Smith K. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002;346:557–563. doi: 10.1056/NEJMoa003289
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa003289&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=11856794&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F05%2F24%2F2023.05.22.23290369.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000173926700003&link_type=ISI) 

23. 23. Group HaCAS. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. New England Journal of Medicine. 2002;346:549–556.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa012689&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=11856793&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F05%2F24%2F2023.05.22.23290369.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000173926700002&link_type=ISI) 

24. 24.Investigators A, Group ACT, Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, Cooper DJ, Higgins AM, Holdgate A, et al. Goal-directed resuscitation for patients with early septic shock. N Engl J Med. 2014;371:1496–1506. doi: 10.1056/NEJMoa1404380
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa1404380&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25272316&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F05%2F24%2F2023.05.22.23290369.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000342994700006&link_type=ISI) 

25. 25.Weng TI, Huang CH, Ma MH, Chang WT, Liu SC, Wang TD, Chen WJ. Improving the rate of return of spontaneous circulation for out-of-hospital cardiac arrests with a formal, structured emergency resuscitation team. Resuscitation. 2004;60:137–142. doi: 10.1016/j.resuscitation.2003.09.007
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.resuscitation.2003.09.007&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=15036730&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F05%2F24%2F2023.05.22.23290369.atom) 

26. 26.Galpern D, Guerrero A, Tu A, Fahoum B, Wise L. Effectiveness of a central line bundle campaign on line-associated infections in the intensive care unit. Surgery. 2008;144:492–495; discussion 495. doi: 10.1016/j.surg.2008.06.004
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.surg.2008.06.004&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18847630&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F05%2F24%2F2023.05.22.23290369.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000259751000002&link_type=ISI) 

27. 27.Kjaergaard J, Moller JE, Schmidt H, Grand J, Molstrom S, Borregaard B, Veno S, Sarkisian L, Mamaev D, Jensen LO, et al. Blood-Pressure Targets in Comatose Survivors of Cardiac Arrest. N Engl J Med. 2022;387:1456–1466. doi: 10.1056/NEJMoa2208687
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2208687&link_type=DOI) 

28. 28.Schmidt H, Kjaergaard J, Hassager C, Molstrom S, Grand J, Borregaard B, Roelsgaard Obling LE, Veno S, Sarkisian L, Mamaev D, et al. Oxygen Targets in Comatose Survivors of Cardiac Arrest. N Engl J Med. 2022;387:1467–1476. doi: 10.1056/NEJMoa2208686
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2208686&link_type=DOI)